EAM Investors’s Corcept Therapeutics CORT Stock Holding History

EAM Investors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-59,534	Closed	-$4.37M	–	275
2025 Q2	$4.37M	Sell	59,534 -7,661	-11%	-$555K	0.66%	64
2025 Q1	$7.68M	Buy	+67,195	New	+$4.09M	1.33%	1
2023 Q4	–	Sell	-59,809	Closed	-$1.63M	–	265
2023 Q3	$1.63M	Buy	+59,809	New	+$1.73M	0.31%	144
2022 Q4	–	Sell	-54,651	Closed	-$1.4M	–	274
2022 Q3	$1.4M	Buy	+54,651	New	+$1.46M	0.3%	144
2017 Q4	–	Sell	-72,542	Closed	-$1.4M	–	309
2017 Q3	$1.4M	Sell	72,542 -4,101	-5%	-$61.1K	0.19%	229
2017 Q2	$904K	Sell	76,643 -12,747	-14%	-$139K	0.15%	208
2017 Q1	$980K	Sell	89,390 -154,548	-63%	-$1.36M	0.15%	194
2016 Q4	$1.77M	Buy	+243,938	New	+$1.91M	0.24%	213
2015 Q3	–	Sell	-223,452	Closed	-$1.34M	–	301
2015 Q2	$1.34M	Sell	223,452 -1,089	-0.5%	-$6.68K	0.16%	250
2015 Q1	$1.26M	Buy	+224,541	New	+$813K	0.15%	272

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

EAM Investors's CORT Position: Q3 2025 in Review

EAM Investors sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 59,534 shares — an estimated $4.37M sold.

EAM Investors first reported a position in CORT in Q1 2015 and held it in 10 quarters. The position peaked at $7.68M in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

EAM Investors reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
EAM Investors sold 59,534 Corcept Therapeutics shares in Q3 2025, an estimated $4.37M.
EAM Investors first reported a position in Corcept Therapeutics in Q1 2015 and held it in 10 quarters.
EAM Investors's Corcept Therapeutics position peaked at $7.68M in Q1 2025.
429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.